. Author manuscript; available in PMC: 2010 Dec 6.

Published in final edited form as: Transplant Proc. 1993 Feb;25(1 Pt 1):628–634.

Table 5.

Incidence, FK 506 Trough Plasma Levels, and Outcome of Neurotoxicity, Hyperkalemia, Hypertension, and Glucose Intolerance

	Neurotoxicity	Hyperkalemia	Hypertension	Glucose Intolerance
	Neurotoxicity	Hyperkalemia	Hypertension	Early	Late
No. patients	31 (8.4%)	239 (64.6%)	122 (32.9%)	61 (17.7%)	18(5.2%)
FK 506 levels (ng/mL)
At start	3.3 ± 3.4	1.6 ± 1.4	1.8 ± 1.9	4.5 ± 4.1	2.7 ± 2.8
At end	1.9 ± 3.1	0.7 ± 0.5	0.9 ± 0.7	1.9 ±3.1	1.6 ±2.5
Median time of occurrence (d)	10	23	52	1	152
Outcome [no. patients (%)]
Death during episode	1 (3.2%)	6 (2.5%)	6 (4.9%)	15 (24.6%)	4 (22.2%)
Still present	1 (3.2%)	169 (70.7%)	103 (84.4%)	23 (37.7%)	11 (61.1%)
Complete recovery	29 (93.6%)	64 (26.8%)	13 (10.7%)	23 (37.7%)	3 (16.7%)